On April 22, 2026 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, reported that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)", clinical trial identifier, NCT06332092. This is a Phase 2 study designed to evaluate the efficacy of different dosing regimens as well as to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-L1-based immune checkpoint inhibitor.
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, "We are honored to be selected by ASCO (Free ASCO Whitepaper) to present our findings on the interim data of our Phase 2 results for FID-007. We are encouraged by the clinical progress achieved so far and believe in the potential of FID-007 for the treatment of (R/M) HNSCC patients, currently having very few effective treatment options."
Details of the presentation are as follows:
Abstract Title: FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Session: Head and Neck Cancer Track Rapid Oral Abstract Session from 4:30pm to 6pm (CDT) within hall D1 of McCormick Place, Chicago.
Presenter: Guilherme Rabinowits, MD, senior member of the Head and Neck-Endocrine Oncology Department at Moffitt Cancer Center.
Authors: Guilherme Rabinowits, Christine H. Chung, Aditya Shreenivas, Eric S. Nadler, Donald A. Richards, Nabil F. Saba, Ray Yin, Jorge J. Nieva, Jacob S. Thomas.
Presentation Date and Time: Monday, June 1, 2026, from 4:30pm to 6:00pm.
Presentation Type: Rapid Oral Abstract Session within the Head and Neck Cancer Track Session.
Abstract #6020.
The abstract will be available on the ASCO (Free ASCO Whitepaper) website on May 21, 2026, at 5:00pm EST. The full presentation will be available on Fulgent’s investor relations website at the start of the session.
(Press release, Fulgent Genetics, APR 22, 2026, View Source [SID1234664703])